Abstract
The p53 tumour suppressor protein is tightly regulated by protein-protein association, protein turnover and a variety of post-translational modifications. Multisite phosphorylation plays a major role in activating and in finely tuning p53 function. The proline rich domain of murine p53 is a substrate for phosphorylation, in vitro and in cultured cells, by the p42ERK2 and p44ERK1 mitogen-activated protein (MAP) kinases. However, to date there have been no reports of attempts to determine whether p53 from any other species is a substrate for MAP kinase. In this paper we confirm that murine p53 is targeted by recombinant MAP kinase and by MAP kinases in extracts of both murine and human cells. In contrast, human p53 is not a substrate for recombinant MAP kinase nor are there any detectable levels of protein kinase activity in stimulated human cell extracts which phosphorylate the proline rich domain of human p53 in vitro. Finally, although stimulation of murine fibroblasts with o-tetradecanolylphorbol 13-acetate (TPA), an indirect activator of the MAP kinase pathway, leads to site-specific phosphorylation of murine p53, similar treatment of human fibroblasts and epithelial cells showed no significant changes in the phosphorylation pattern. These data are consistent with accumulating evidence that significant species-dependent differences exist in the post-translational modification of p53.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Adler V, Pincus MR, Minamoto T, Fuchs SY, Bluth MJ, Brandt-Rauf PW, Friedman FK, Robinson RC, Chen JM, Wang XW, Harris CC and Ronai Z. . 1997 Proc. Natl. Acad. Sci. USA 94: 1686–1691.
Agarwal ML, Taylor WR, Chernov MV, Chernova OB and Stark GR. . 1998 J. Biol. Chem. 273: 1–4.
Campbell SL, Khosravi-Far R, Rossman KL, Clark GJ and Der CJ. . 1998 Oncogene 17: 1395–1413.
Cowley S, Paterson H, Kemp P and Marshall CJ. . 1994 Cell 77: 841–852.
Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CJ, Butel JS and Bradley A. . 1992 Nature 356: 215–221.
Fukasawa K, Wiener F, Vande Woude GF and Mai S. . 1997 Oncogene 15: 1295–1302.
Gavin A-C and Nebreda AP. . 1999 Curr. Biol. 9: 281–284.
Giaccia AJ and Kastan MB. . 1998 Genes Dev. 12: 2973–2983.
Gonzalez FA, Raden DL and Davis RJ. . 1991 J. Biol. Chem. 266: 22159–22163.
Hollstein M, Shomer B, Greenblatt M, Soussi T, Hovig E, Montesano R and Harris CC. . 1996 Nucleic. Acids Res. 24: 141–146.
Hu MC-T, Qui WR and Wang Y-P. . 1997 Oncogene 15: 2277–2287.
Jacobs D, Glossip D, Xing H, Muslin AJ and Kornfeld K. . 1999 Genes Dev. 13: 163–175.
Knippschild U, Milne DM, Campbell LE, DeMaggio AJ, Christenson E, Hoekstra MF and Meek DW. . 1997 Oncogene 15: 1727–1736.
Ko LJ, Shieh S-Y, Chen X, Jayaraman L, Tamai K, Taya Y, Prives C and Pan Z-Q. . 1997 Mol. Cell. Biol. 17: 7220–7229.
Lees-Miller S, Sakaguchi K, Ullrich SJ, Appella E and Anderson CW. . 1992 Mol. Cell Biol. 12: 5041–5049.
Lees-Miller SP, Chen Y-R and Anderson CW. . 1990 Mol. Cell Biol. 10: 6472–6481.
Livingstone LR, White A, Sprouse J, Livanos E, Jacks T and Tlsty TD. . 1992 Cell 70: 923–935.
Mansour SJ, Matten WT, Hermann AS, Candia JM, Rong S, Fukasawa K, Vande Woude GF and Ahn NG. . 1994 Science 265: 966–970.
Meek DW. . 1997 Pathologie Biologie 45: 804–814.
Meek DW. . 1998 Cellular Signalling 10: 159–166.
Milne DM, Campbell DG, Caudwell FB and Meek DW. . 1994 J. Biol. Chem. 269: 9253–9260.
Milne DM, Campbell L, Campbell DG and Meek DW. . 1995 J. Biol. Chem. 270: 5511–5518.
Milne DM, McKendrick L, Jardine LJ, Deacon E, Lord JM and Meek DW. . 1996 Oncogene 13: 205–211.
Muller E and Scheidtmann K-H. . 1995 Oncogene 10: 1175–1185.
Patschinsky T, Knippschild U and Deppert W. . 1992 J. Virol. 66: 3846–3859.
Prives C and Hall PA. . 1999 J. Path. 187: 112–126.
Robinson MJ and Cobb MH. . 1997 Curr. Op. Cell Biol. 9: 180–186.
Ruaro EM, Collavin L, Del Sal G, Haffner R, Oren M, Levine AJ and Schneider C. . 1997 Proc. Natl. Acad. Sci. USA 94: 4675–4680.
Sakamuro D, Sabbatini P, White E and Prendergast GC. . 1997 Oncogene 15: 887–898.
Songyang Z, Lu KP, Kwon YT, Tsai L-H, Filhol O, Cochet C, Brickey DA, Soderling TR, Bartleson C, Graves DJ, DeMaggio AJ, Hoekstra MF, Blenis J, Hunter T and Cantley LC. . 1996 Mol. Cell. Biol. 16: 6486–6493.
Soussi T and May P. . 1996 J. Mol. Biol. 260: 623–637.
Venot C, Maratrat M, Dureuil C, Conseiller E, Bracco L and Debussche L. . 1998 EMBO J. 17: 4668–4679.
Walker KK and Levine AJ. . 1996 Proc. Natl. Acad. Sci. USA 93: 15335–15340.
Waterman MJF, Stavridi ES, Waterman JLF and Halazonetis TD. . 1998 Nature Genetics 19: 175–178.
Yang S-H, Whitmarsh AJ, Davis RJ and Sharrocks AD. . 1998 EMBO J. 17: 1740–1749.
Yin Y, Tainsky MA, Bischoff FZ, Strong LC and Wahl GM. . 1992 Cell 70: 937–948.
Acknowledgements
This work was supported by the Association for International Cancer Research. DW Meek is a Medical Research Council Senior Fellow.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jardine, L., Milne, D., Dumaz, N. et al. Phosphorylation of murine p53, but not human p53, by MAP kinase in vitro and in cultured cells highlights species-dependent variation in post-translational modification. Oncogene 18, 7602–7607 (1999). https://doi.org/10.1038/sj.onc.1203137
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1203137
Keywords
This article is cited by
-
The codon 72 polymorphism-specific effects of human p53 are absent in mouse cells: implications on generation of mouse models
Oncogene (2007)
-
Regulation of p53 responses by post-translational modifications
Cell Death & Differentiation (2003)